Osteoporosis 2016 | Pregnancy associated osteoporosis: Dr Ashok Bhalla #osteo2016
Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amongst type 2 diabetic...
-
Upload
national-osteoporosis-society -
Category
Healthcare
-
view
58 -
download
0
Transcript of Osteoporosis 2016 | Antidiabetic medication use and the risk of fracture amongst type 2 diabetic...
Antidiabetic Medication Use and Fracture Risk in T2DM Patients:
a nested case-control study
M Sanni Ali, Eladio L, Berta S, Dídac M, and Daniel Prieto-Alhambra
National Osteoporosis Conference 2016
Introduction
Type 2 diabetes (T2DM) is associated with increased bone mineral density (BMD) and higher risk of fracture.
Existing prediction tools such as FRAX underestimate fracture risk.
Hypoglycaemic treatment could modulate the risk of fractures in many ways.
Observational studies on the effect of antidiabetic medications have conflicting findings.
Some studies reported higher risk of fractures in insulin-treated patients:
- Higher prevalence of diabetic complications/comorbidities.
- Higher risk of hypoglycaemic episodes and falls.
Introduction
Only few studies have looked at the comparative safety of different antidiabetic medications.
Palermo A et al. Osteoporos Intl 2015
Introduction
Aim: To investigate the comparative fracture risk associated with the different antidiabetic medications in primary care practice.
Methods
Data source: SIDIAP database- One primary care health provider using one same e-records
software.- 274 Primary Care Centres in Catalonia - > 3,400 GPs.- > 5 million patients (>80% population).- > 55 million person-years of research-usable data (2005 onwards).
Study participants:
- Incident T2DM patients registered in SIDIAP, aged 40 years or older, with an eGFR >15 at T2DM diagnosis.
Methods
Methods
Study period: 1st January 2006 - 31st December 2013
Design: Nested case-control study.
Exposure: Antidiabetic medications (Reference = Metformin)
Outcome: Osteoporotic fracture (cases)
Exclusion Criteria:
- Patients having fractures before entry date. - T2DM diagnosis date before 1st January 2006 or practice
registration date or within the last year of the study period.- Patients with chronic kidney failure (eGFR <15).- Patients < 40 years of age on the date of T2DM diagnosis.
Methods
Cases were (risk set) matched with up to 5 controls on (“epi” package)• 10-year bands on calendar year of birth • Calendar year of cohort entry (T2DM cohort)• Gender
Multiple imputation with chained equation was used to impute missing data (“mice” in R).
Conditional logistic regression was used to estimate OR and 95%CI adjusting for the confounders listed in the baseline table (ccwc, R).
Potential confounders: demographic variables, comorbidities (eGFR and HBA1c), comedication, life style factors (Smoking, Alcohol use, socioeconomic status)
Results
166,106 Patients
102,564 patients :T2DX (< 2006) = 90,183 T2DM (in 2013) = 8,490 T2DM<practice reg. = 17,759eGFR (≤15) = 166Date entry<= Date exit = 328Age at Index < 40 = 319Fracture before cohort entry = 1,455 *Not mutually exclusive
62,087 PatientsCases = 2,049Controls = 60,038
12,277 Case-controlsCases = 2,049Controls = 10,228
49,810 Unmatched PatientsCases = 0
Controls = 49,810
Flow chart of data extraction for T2DM cohort and case-control
Results
Table: Baseline Characteristics of Cases and Controls
ResultsTable: Association Between Different Antidiabetic Medications and Risk of
Fracture
Total
(N= 12,277)Cases
(N=2,049)
Adjusted
Odds Ratio 95% CI
Metformin 4079 625 REFERENCE
Insulin 546 126 1.63 1.30 2.04
Sulfonylurea 697 119 1.13 0.91 1.41
Gliptins:DPP4 77 14 1.21 0.67 2.19Insulin +
Metformin 329 58 1.22 0.89 1.65
Metformin and Sulfonylurea 946 177 1.29 1.07 1.56
Metformin and DPP4 218 36 1.12 0.77 1.62Adjusted for age/sex, comedications, comorbidities, BMI, eGFR, HBA1c, smoking,
alcohol use and socioeconomic Status.
Results
Table: Timing of Insulin Use and Fracture Risk
Total Cases Odds Ratio 95% CI
Never Users Past 2 Years 3933 666 1.00 Current Users- Previous 6 Months 470 116 1.52 1.19 1.93Recent Users- Between Previous 6 and 12 Months 78 14 1.02 0.57 1.85Past Users- Between 12 and 18 Months 37 7 1.19 0.51 2.74Previous Past Users- Between 18 and 24 Months 22 2 0.46 0.10 2.00
Discussion
Insulin treatment is associated with increased risk of fractures compared to metformin.
Fracture risk appears to increase during insulin use (6-months) and disappear with insulin discontinuation.
Strengths: adjustment was possible for several confounders including HBA1c, eGFR, among others.
Limitations: Power and unmeasured confounding could still explain the observed association.